Drugs / Foretinib
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT00920192 | Aug 2009 → Mar 2012 | hepatocellular carcinoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00742261 | Aug 2008 → Jun 2009 | cancer | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00743067 | Aug 2006 → May 2009 | cancer | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00742131 | Mar 2005 → May 2008 | cancer | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01138384 | Oct 2010 → May 2014 | breast cancer | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT02034097 | Apr 2014 | cancer | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 2 | NCT01147484 | Sep 2010 → Dec 2014 | breast carcinoma | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 2 | NCT00725764 | Aug 2007 → May 2009 | head and neck carcinoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00725712 | Mar 2007 → Nov 2009 | digestive system neoplasm | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00726323 | Jun 2006 → Aug 2010 | renal cell carcinoma | GlaxoSmithKline | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01068587 Comparator | Jan 2010 → Mar 2014 | lung cancer | NCIC Clinical Trials Group | Completed | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | foretinib | “GSK1363089 (foretinib)” NCT00725764 ↗ |
| Known as | EXEL-2880 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1230609 ↗ |
| Known as | GSK-089 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1230609 ↗ |
| Known as | GSK-1363089G | ChEMBL registry synonym — accepted as the source's own label CHEMBL1230609 ↗ |
| Known as | GSK1363089 | “The purpose of this study is to assess the safety and tolerability of foretinib (also known as GSK1363089) when used in the treatment of patients with advanced hepatocellular...” NCT00920192 ↗6“Foretinib (GSK1363089) is an investigational, oral, multikinase inhibitor involved in invasion, migration, and angiogenesis.” NCT02034097 ↗ |
| Known as | GSK1363089 (formerly XL880) | “GSK1363089 (formerly XL880)” NCT00725764 ↗ |
| Known as | XL880 | “A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors” NCT00742131 ↗ |
| Action | Inhibit | “Stem cell growth factor receptor inhibitor” CHEMBL1230609 ↗2“Tyrosine-protein kinase TIE-2 inhibitor” CHEMBL1230609 ↗ “c-MET tyrosine kinase inhibitor” NCT00725712 ↗ |
| Modality | Small molecule | “GSK1363089 is a new chemical entity” NCT00725764 ↗ |
| Route | Oral | “GSK1363089 (XL880) Administered Orally” NCT00725712 ↗ |
| Target | KIT | “Stem cell growth factor receptor inhibitor” CHEMBL1230609 ↗ |
| Target | MET | “c-MET tyrosine kinase inhibitor” NCT00725712 ↗ |
| Target | TEK | “Tyrosine-protein kinase TIE-2 inhibitor” CHEMBL1230609 ↗ |